Valuation: Novacyt

Market Cap 34.22M 38.52M 31.94M 29.11M 54.9M 3.7B 55.42M 387M 150M 1.89B 145M 141M 6.07B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 36.18M 40.72M 33.77M 30.78M 58.04M 3.91B 58.58M 409M 158M 2B 153M 150M 6.42B EV / Sales 2026 *
1.19x
EV / Sales 2027 * 1.12x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day-4.66%
1 week-11.24%
Current month-9.09%
1 month-12.11%
3 months+12.36%
6 months+20.81%
Current year+15.09%
1 week 0.44
Extreme 0.445
0.54
1 month 0.44
Extreme 0.445
0.54
Current year 0.29
Extreme 0.29
1.04
1 year 0.29
Extreme 0.29
1.04
3 years 0.29
Extreme 0.29
1.59
5 years 0.29
Extreme 0.29
5.89
10 years 0.06
Extreme 0.0612
13.96
Manager TitleAgeSince
Chief Executive Officer 53 2024-04-30
Director of Finance/CFO 44 2019-12-31
Chief Operating Officer - 2021-10-31
Director TitleAgeSince
Director/Board Member 75 2006-07-02
Director/Board Member 60 2017-06-26
Director/Board Member 44 2024-01-01
Date Insider Type Main position Quantity % Market Cap. Importance
3/30/26 Buy

Chief Executive Officer

1,792 0.0025%
3/30/26 Buy

Chairman

15,228 0.0216%
3/30/26 Buy

Chairman

56,732 0.0803%
Change 5-day change 1-year change 3-year change Capi.($)
-4.66%-11.24%-6.93%-37.11% 38.53M
+4.16%+3.04%+49.37%+94.17% 74.41B
-3.11%-3.53%+21.92%+74.60% 59.26B
+0.89%-0.63%+4.28%+34.51% 47.14B
-0.82%-4.47%+26.40%+33.22% 42.91B
-0.17%+0.88%+352.47%+690.14% 44.13B
-1.59%-2.12%+2.33%+97.87% 40.79B
-0.54%+2.93%+9.50%+50.41% 30.77B
-2.68%+5.11%+33.11%+19.50% 29.31B
+0.92%-7.38%-28.58%+330.17% 23.71B
Average -0.74%-1.23%+46.39%+138.75% 39.25B
Weighted average by Cap. -0.02%-0.40%+57.43%+150.02%

Financials

2026 *2027 *
Net sales 30.52M 34.36M 28.49M 25.97M 48.98M 3.3B 49.43M 345M 134M 1.69B 129M 126M 5.42B 34.86M 39.24M 32.54M 29.66M 55.93M 3.77B 56.45M 394M 153M 1.93B 147M 144M 6.19B
Net income - -
Net Debt 1.96M 2.2M 1.83M 1.66M 3.14M 212M 3.17M 22.09M 8.56M 108M 8.27M 8.09M 347M 4.84M 5.45M 4.52M 4.12M 7.77M 524M 7.84M 54.69M 21.19M 268M 20.46M 20.02M 860M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
26-10-02 €0.4500 -4.66% 271,083
26-10-01 €0.4720 -4.65% 377,585
26-09-30 €0.4950 -2.17% 446,734
26-09-29 €0.5060 -1.75% 303,342
26-09-28 €0.5150 +1.58% 128,558

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNOV Stock